Changchun BCHT Biotechnology Co.

SHSE:688276 Stock Report

Market Cap: CN¥9.0b

Changchun BCHT Biotechnology Future Growth

Future criteria checks 5/6

Changchun BCHT Biotechnology is forecast to grow earnings and revenue by 45.8% and 36.2% per annum respectively. EPS is expected to grow by 41.6% per annum. Return on equity is forecast to be 17.8% in 3 years.

Key information

45.8%

Earnings growth rate

41.6%

EPS growth rate

Biotechs earnings growth44.3%
Revenue growth rate36.2%
Future return on equity17.8%
Analyst coverage

Low

Last updated16 Apr 2025

Recent future growth updates

Recent updates

Changchun BCHT Biotechnology (SHSE:688276) Seems To Use Debt Quite Sensibly

Jan 03
Changchun BCHT Biotechnology (SHSE:688276) Seems To Use Debt Quite Sensibly

Market Might Still Lack Some Conviction On Changchun BCHT Biotechnology Co. (SHSE:688276) Even After 36% Share Price Boost

Oct 07
Market Might Still Lack Some Conviction On Changchun BCHT Biotechnology Co. (SHSE:688276) Even After 36% Share Price Boost

Analysts Just Slashed Their Changchun BCHT Biotechnology Co. (SHSE:688276) EPS Numbers

Aug 22
Analysts Just Slashed Their Changchun BCHT Biotechnology Co. (SHSE:688276) EPS Numbers

Changchun BCHT Biotechnology Co. (SHSE:688276) Doing What It Can To Lift Shares

Jul 28
Changchun BCHT Biotechnology Co. (SHSE:688276) Doing What It Can To Lift Shares

Is Changchun BCHT Biotechnology (SHSE:688276) Using Too Much Debt?

Jun 19
Is Changchun BCHT Biotechnology (SHSE:688276) Using Too Much Debt?

Changchun BCHT Biotechnology Co. (SHSE:688276) Shares Slammed 25% But Getting In Cheap Might Be Difficult Regardless

Apr 16
Changchun BCHT Biotechnology Co. (SHSE:688276) Shares Slammed 25% But Getting In Cheap Might Be Difficult Regardless

We Think That There Are Issues Underlying Changchun BCHT Biotechnology's (SHSE:688276) Earnings

Mar 30
We Think That There Are Issues Underlying Changchun BCHT Biotechnology's (SHSE:688276) Earnings

Earnings and Revenue Growth Forecasts

SHSE:688276 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20263,7991,192N/A1,1431
12/31/20252,677844N/A8722
12/31/20241,971527N/A8753
9/30/20241,608414-176365N/A
6/30/20241,883527-195265N/A
3/31/20241,916543-249252N/A
12/31/20231,825501-215255N/A
9/30/20231,449301-260254N/A
6/30/20231,190219-308141N/A
3/31/20231,113183-185117N/A
12/31/20221,071182-25140N/A
9/30/20221,123222-12674N/A
6/30/20221,061179-301101N/A
3/31/20221,093205-414138N/A
12/31/20211,202244-493140N/A
9/30/20211,304309-486141N/A
6/30/20211,424377-280230N/A
3/31/20211,489424-189191N/A
12/31/20201,441418-127209N/A
12/31/2019976221104233N/A
12/31/20181,01912889270N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688276's forecast earnings growth (45.8% per year) is above the savings rate (2.7%).

Earnings vs Market: 688276's earnings (45.8% per year) are forecast to grow faster than the CN market (23.7% per year).

High Growth Earnings: 688276's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 688276's revenue (36.2% per year) is forecast to grow faster than the CN market (12.6% per year).

High Growth Revenue: 688276's revenue (36.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688276's Return on Equity is forecast to be low in 3 years time (17.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/18 17:34
End of Day Share Price 2025/04/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Changchun BCHT Biotechnology Co. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullChina International Capital Corporation Limited
Yizheng YangChina International Capital Corporation Limited
Yizhang ZhuCitic Securities Co., Ltd.